In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).
News|Articles|July 2, 2026
FDA news in pediatrics: June 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A look back at the FDA approvals, regulatory decisions, and pipeline updates in the pediatric health care space from June 2026.
Advertisement
Advertisement
Another month has come and gone, and with it, several FDA approvals and regulatory updates related to the ever-evolving landscape of pediatric health care.
Related to this article
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.
Advertisement
Advertisement